Floater

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

Retrieved on: 
Friday, March 8, 2024

TARRYTOWN, N.Y., March 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for EYLEA® HD (aflibercept) Injection 8 mg. Specifically, the publications detailed data demonstrating that EYLEA HD extended dosing regimens were non-inferior to EYLEA® (aflibercept) Injection 2 mg for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Key Points: 
  • Specifically, the publications detailed data demonstrating that EYLEA HD extended dosing regimens were non-inferior to EYLEA® (aflibercept) Injection 2 mg for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
  • “Less than a year after its approval, EYLEA HD has already made an impact in the treatment of wet age-related macular degeneration and diabetic macular edema.
  • EYLEA HD has provided disease control for my tough-to-treat cases of diabetic eye disease and allowed both my diabetic and wet age-related macular degeneration patients to enjoy less frequent dosing with a similar safety profile to EYLEA.”
    PULSAR and PHOTON are two double-masked, active-controlled pivotal trials evaluating EYLEA HD compared to EYLEA.
  • In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.

SightMD Welcomes Cynthia Zara, OD to its expert team in New York

Retrieved on: 
Monday, March 4, 2024

HAUPPAUGE, N.Y., March 4, 2024 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.

Key Points: 
  • SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.
  • HAUPPAUGE, N.Y., March 4, 2024 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.
  • Cynthia Zara, OD is a board-certified optometrist providing dilation exams, contact lenses and eyeglasses, dry eye treatments, and more.
  • When asked what she is looking forward to most about joining the SightMD Team, Dr Zara said "I am excited to be joining SightMD in Hamptons Bays and Southampton.

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Retrieved on: 
Monday, January 8, 2024

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.
  • This feature helps to ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.
  • The platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter.
  • “FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said George Waring IV, M.D., ophthalmologist and founder and medical director, Waring Vision Institute, Mt.

Eco Wave Power Commences Sending of Clean Electricity to the Israeli National Electrical Grid

Retrieved on: 
Wednesday, January 3, 2024

TEL AVIV, Israel, Jan. 3, 2024 /PRNewswire/ -- Eco Wave Power Global AB (publ) (Nasdaq: WAVE) ("Eco Wave Power" or the "Company"), a leading, publicly traded onshore wave energy company, is pleased to announce that it has commenced sending of clean electricity from its EWP-EDF One project in the Port of Jaffa, to the Israeli National Electrical grid.

Key Points: 
  • TEL AVIV, Israel, Jan. 3, 2024 /PRNewswire/ -- Eco Wave Power Global AB (publ) (Nasdaq: WAVE) ("Eco Wave Power" or the "Company"), a leading, publicly traded onshore wave energy company, is pleased to announce that it has commenced sending of clean electricity from its EWP-EDF One project in the Port of Jaffa, to the Israeli National Electrical grid.
  • Eco Wave Power has recently finalized the construction of the EWP-EDF One project in the Port of Jaffa, in Israel.
  • In August 2023, the power station was officially connected to the Israeli national electrical grid, marking the first time in the history of Israel, that electricity produced by the power of the waves is sent to the national electrical grid of the country.
  • During a recent storm, the Eco Wave Power engineering team tested the operation of the power station, in waves up to 3.5 meters.

Eco Wave Power Commences Sending of Clean Electricity to the Israeli National Electrical Grid

Retrieved on: 
Wednesday, January 3, 2024

TEL AVIV, Israel, Jan. 3, 2024 /PRNewswire/ -- Eco Wave Power Global AB (publ) (Nasdaq: WAVE) ("Eco Wave Power" or the "Company"), a leading, publicly traded onshore wave energy company, is pleased to announce that it has commenced sending of clean electricity from its EWP-EDF One project in the Port of Jaffa, to the Israeli National Electrical grid.

Key Points: 
  • TEL AVIV, Israel, Jan. 3, 2024 /PRNewswire/ -- Eco Wave Power Global AB (publ) (Nasdaq: WAVE) ("Eco Wave Power" or the "Company"), a leading, publicly traded onshore wave energy company, is pleased to announce that it has commenced sending of clean electricity from its EWP-EDF One project in the Port of Jaffa, to the Israeli National Electrical grid.
  • Eco Wave Power has recently finalized the construction of the EWP-EDF One project in the Port of Jaffa, in Israel.
  • In August 2023, the power station was officially connected to the Israeli national electrical grid, marking the first time in the history of Israel, that electricity produced by the power of the waves is sent to the national electrical grid of the country.
  • During a recent storm, the Eco Wave Power engineering team tested the operation of the power station, in waves up to 3.5 meters.

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

SBM Offshore Third Quarter 2023 Trading Update

Retrieved on: 
Thursday, November 9, 2023

The Company’s Total Recordable Injury Frequency Rate year-to-date was 0.09, compared with the full year 2023 target of below 0.143.

Key Points: 
  • The Company’s Total Recordable Injury Frequency Rate year-to-date was 0.09, compared with the full year 2023 target of below 0.143.
  • The purchase allows ExxonMobil Guyana to assume ownership of the unit while SBM Offshore will continue to operate and maintain the FPSO up to 2033.
  • SBM Offshore has scheduled a conference call, which will be followed by a Q&A session, to discuss the Third Quarter 2023 Trading Update.
  • SBM Offshore designs, builds, installs and operates offshore floating facilities for the offshore energy industry.

Valaris Reports Third Quarter 2023 Results

Retrieved on: 
Tuesday, November 7, 2023

Valaris Limited (NYSE: VAL) ("Valaris" or the "Company") today reported third quarter 2023 results.

Key Points: 
  • Valaris Limited (NYSE: VAL) ("Valaris" or the "Company") today reported third quarter 2023 results.
  • Net income was $17 million compared to net loss of $27 million in the second quarter 2023.
  • Revenues increased to $122 million from $118 million in the second quarter 2023 primarily due to more operating days resulting from less out of service time for planned maintenance during the third quarter.
  • Revenues increased to $46 million from $43 million in the second quarter 2023 and contract drilling expense increased to $19 million from $18 million in the second quarter.

Public advisory - Unauthorized health products seized from online retailer "UU Zone" may pose serious health risks

Retrieved on: 
Wednesday, October 25, 2023

Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.
  • The products are labelled to contain medicinal drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Read product labels to verify that health products have been authorized for sale by Health Canada.

EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)

Retrieved on: 
Friday, August 18, 2023

TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). The recommended dose for EYLEA HD is 8 mg (0.07 mL of 114.3 mg/mL solution) every 4 weeks (monthly) for the first 3 months across all indications, followed by 8 mg every 8 to 16 weeks (2 to 4 months) in wAMD and DME and every 8 to 12 weeks (2 to 3 months) for DR.

Key Points: 
  • TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR).
  • “More than 10 years ago, we fundamentally changed the way that certain serious retinal diseases were treated with the introduction of EYLEA.
  • EYLEA 4U helps patients understand how EYLEA HD may be covered by their health insurance plans and assists eligible patients who need financial assistance for their EYLEA HD prescription.
  • In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.